IN8bio (NASDAQ:INAB) Given New $6.00 Price Target at HC Wainwright

IN8bio (NASDAQ:INAB) had its target price decreased by equities researchers at HC Wainwright from $8.00 to $6.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

IN8bio Trading Down 9.0 %

INAB opened at $0.23 on Friday. IN8bio has a fifty-two week low of $0.22 and a fifty-two week high of $1.74. The firm has a market capitalization of $18.39 million, a PE ratio of -0.30 and a beta of 0.03. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.84 and a quick ratio of 1.84. The company’s 50-day moving average is $0.28 and its 200 day moving average is $0.30.

IN8bio (NASDAQ:INAB) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03. As a group, research analysts predict that IN8bio will post -0.56 earnings per share for the current fiscal year.

Institutional Trading of IN8bio

Several institutional investors and hedge funds have recently bought and sold shares of INAB. Jane Street Group LLC boosted its position in IN8bio by 296.7% during the fourth quarter. Jane Street Group LLC now owns 115,919 shares of the company’s stock valued at $30,000 after buying an additional 86,696 shares during the period. Geode Capital Management LLC grew its stake in shares of IN8bio by 56.5% in the fourth quarter. Geode Capital Management LLC now owns 515,193 shares of the company’s stock worth $133,000 after acquiring an additional 185,919 shares during the last quarter. Sigma Planning Corp increased its position in shares of IN8bio by 22.3% during the fourth quarter. Sigma Planning Corp now owns 1,041,380 shares of the company’s stock valued at $268,000 after acquiring an additional 190,100 shares in the last quarter. AIGH Capital Management LLC increased its holdings in IN8bio by 269.7% in the 4th quarter. AIGH Capital Management LLC now owns 6,191,865 shares of the company’s stock worth $1,593,000 after buying an additional 4,517,227 shares in the last quarter. Finally, Alyeska Investment Group L.P. boosted its stake in shares of IN8bio by 1,064.5% in the 4th quarter. Alyeska Investment Group L.P. now owns 5,063,291 shares of the company’s stock worth $1,302,000 after buying an additional 4,628,482 shares during the last quarter. 92.05% of the stock is currently owned by hedge funds and other institutional investors.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.